Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children
NCT ID: NCT04569357
Last Updated: 2024-08-01
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE3
Total Enrollment
363 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-11-20
Study Completion Date
2022-02-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Purpose of the study:
• evaluate the efficacy and safety of Prospekta in the treatment of attention deficit/hyperactivity disorder in children.
• evaluate the efficacy and safety of Prospekta in the treatment of attention deficit/hyperactivity disorder in children.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of SPD465 in Adults With ADHD
NCT00150579
Attention Deficit Disorder With Hyperactivity
COMPLETED
PHASE3
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
NCT02734693
Attention-Deficit Hyperactivity Disorder (ADHD)
COMPLETED
PHASE3
Adult Attention Deficit Hyperactivity Disorder
NCT01692782
Adult Attention Deficit Hyperactivity Disorder
COMPLETED
PHASE2
Stimulant Effects on Brain Activity
NCT02453698
Healthy Volunteers
COMPLETED
PHASE1
Treating Young Children With Attention Deficit Hyperactivity Disorder
NCT07300956
Attention-Deficit/Hyperactivity Disorder (ADHD)
NOT_YET_RECRUITING
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Design: a multicenter double-blind placebo-controlled parallel-group randomized clinical trial.
The study will enroll children of either age from 7 to 12 years old with diagnosis of attention deficit/hyperactivity disorder (ADHD) verified by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, American Psychiatric Association" \[DSM-V\]).
After signing patient information sheet and informed consent form by the subject's parent/adoptive parent collection of complaints, medical examination of the children, filling Attention Deficit Hyperactivity Disorder-Rating Scale-V \[ADHD-RS-V\]) scale by the parent/adoptive parent will be performed, concomitant therapy will be recorded and laboratory tests will be carried out.
The study will enroll children with total score ADHD-RS-V ≥ 22. If the inclusion criteria were met and there were no exclusion criteria (Day 1), the patient will be randomized to one of the two groups: group 1 will receive Prospekta at 1 tablet twice daily; group 2 will receive Placebo using the study drug dosing regimen.
Treatment period will be 8 weeks, the key examination stages (collection of complaints, recording objective examination findings, repeated filling ADHD-RS-V by parent/adoptive parent) will be made at Visit 1 (Day 1), further in 4 weeks (visit 2) and in 8 weeks (visit 3). Each visit to the research center will be made by the subject accompanied by his/her parent/adoptive parent. Two weeks later (visit 1.1, week 2±3 days) after randomization and initiation of the study therapy and between visits 2 and 3 (visits 2.2, week 6±3 days) the investigator will examine the patient's clinical status (during phone calls). Based on complaints, monitoring of the prescribed therapy therapeutic safety will be assessed. At visit 2 (week 4±3 days) and visit 3 (week 8±3 days) the investigator will collect complaints, record objective examination findings, monitor repeated ADHD-RS-V filling by parent/adoptive parent, the prescribed and concomitant therapy, evaluate therapeutic safety and compliance. In addition at Visit 3 the investigator will complete the Clinical Global Impression Efficacy Index \[CGI-EI\] scale and collect samples for laboratory testing. The study treatments will be completed.
The total length of the observation period is 8 weeks. During the study the treatment for underlying conditions will be allowed with the exception of the drugs indicated in the section "Prohibited concomitant therapy".
The study will enroll children of either age from 7 to 12 years old with diagnosis of attention deficit/hyperactivity disorder (ADHD) verified by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, American Psychiatric Association" \[DSM-V\]).
After signing patient information sheet and informed consent form by the subject's parent/adoptive parent collection of complaints, medical examination of the children, filling Attention Deficit Hyperactivity Disorder-Rating Scale-V \[ADHD-RS-V\]) scale by the parent/adoptive parent will be performed, concomitant therapy will be recorded and laboratory tests will be carried out.
The study will enroll children with total score ADHD-RS-V ≥ 22. If the inclusion criteria were met and there were no exclusion criteria (Day 1), the patient will be randomized to one of the two groups: group 1 will receive Prospekta at 1 tablet twice daily; group 2 will receive Placebo using the study drug dosing regimen.
Treatment period will be 8 weeks, the key examination stages (collection of complaints, recording objective examination findings, repeated filling ADHD-RS-V by parent/adoptive parent) will be made at Visit 1 (Day 1), further in 4 weeks (visit 2) and in 8 weeks (visit 3). Each visit to the research center will be made by the subject accompanied by his/her parent/adoptive parent. Two weeks later (visit 1.1, week 2±3 days) after randomization and initiation of the study therapy and between visits 2 and 3 (visits 2.2, week 6±3 days) the investigator will examine the patient's clinical status (during phone calls). Based on complaints, monitoring of the prescribed therapy therapeutic safety will be assessed. At visit 2 (week 4±3 days) and visit 3 (week 8±3 days) the investigator will collect complaints, record objective examination findings, monitor repeated ADHD-RS-V filling by parent/adoptive parent, the prescribed and concomitant therapy, evaluate therapeutic safety and compliance. In addition at Visit 3 the investigator will complete the Clinical Global Impression Efficacy Index \[CGI-EI\] scale and collect samples for laboratory testing. The study treatments will be completed.
The total length of the observation period is 8 weeks. During the study the treatment for underlying conditions will be allowed with the exception of the drugs indicated in the section "Prohibited concomitant therapy".
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Attention Deficit Hyperactivity Disorder
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
double-blind placebo-controlled randomized
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prospekta
One tablet per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablet should be held in mouth until completely dissolved.
Group Type
EXPERIMENTAL
Prospekta
Intervention Type
DRUG
Oral administration.
Placebo
One tablet per intake 2 times a day (approximately at the same time), outside of meal (between meals or 15 minutes prior to meal or drinking). The tablet should be held in mouth until completely dissolved.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Oral administration.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prospekta
Oral administration.
Intervention Type
DRUG
Placebo
Oral administration.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
MMH-MAP
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male and female children aged 7-12 years old inclusive.
2. Children with verified diagnosis of ADHD.
3. Presence of all ADHD criteria according to DSM-V (see appendix 1):
A. persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development, as characterized by (1) and/or (2):
1. Attention deficit: Six (or more) of the following symptoms have persisted for at least 6 months to a degree that is inconsistent with developmental level and that negatively impacts directly on social and academic/occupational activities:
* Often fails to give close attention to details or makes careless mistakes in schoolwork, at work, or during other activities (e.g., overlooks or misses details, work is inaccurate).
* Often has difficulty sustaining attention in tasks or play activities (e.g., has difficulty remaining focused during lectures, conversations, or lengthy reading).
* Often does not seem to listen when spoken to directly (e.g., mind seems elsewhere, even in the absence of any obvious distraction).
* Often does not follow through on instructions and fails to finish schoolwork, chores, or duties in the workplace (e.g., starts tasks but quickly loses focus and is easily sidetracked).
* Often has difficulty organizing tasks and activities (e.g., difficulty managing sequential tasks; difficulty keeping materials and belongings in order; messy, disorganized work; has poor time management; fails to meet deadlines).
* Often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort (e.g., schoolwork or homework).
* Often loses things necessary for tasks or activities (e.g., school materials, pencils, books, tools, wallets, keys, eyeglasses).
* Is often easily distracted by extraneous stimuli.
* Is often forgetful in daily activities (e.g., doing chores, running errands).
2. Hyperactivity/impulsivity: Six (or more) of the following symptoms have persisted for at least 6 months to a degree that is inconsistent with developmental level and that negatively impacts directly on social and academic/occupational activities. Note. The symptoms are not solely a manifestation of oppositional behavior, defiance, hostility, or failure to understand tasks or instructions.
* Often fidgets with or taps hands or feet or squirms in seat.
* Often leaves seat in situations when remaining seated is expected (e.g., leaves his or her place in the classroom, in the office or other workplace, or in other situations that require remaining in place).
* Often runs about or climbs in situations where it is inappropriate.
* Often unable to play or take part in leisure activities quietly.
* Is often "on the go" acting as if "driven by a motor" (e.g., is unable to be or uncomfortable being still for extended time).
* Often talks excessively.
* Often blurts out an answer before a question has been completed (e.g., completes people's sentences; cannot wait for turn in conversation).
* Often has trouble waiting his/her turn (e.g., while waiting in line).
* Often interrupts or intrudes on others (e.g., butts into conversations, games, or activities; may start using other people's things without asking or receiving permission).
B. Several inattentive or hyperactive-impulsive symptoms were present before age 12 years.
C. Several inattentive or hyperactive-impulsive symptoms are present in two or more settings, (e.g., at home, school or work; with friends or relatives).
D. There is clear evidence that the symptoms interfere with, or reduce the quality of, social, school, or work functioning.
E. The symptoms do not occur exclusively during the course of schizophrenia or another psychotic disorder and are not better explained by another mental disorder (e.g., mood disorder, anxiety disorder, dissociative disorder, personality disorder, substance intoxication or withdrawal).
4\. ADHD-RS-V ≥ 22. 5. Availability of signed information sheet and informed consent form for the parents/adoptive parents for the subject's participation in the clinical trial.
2. Children with verified diagnosis of ADHD.
3. Presence of all ADHD criteria according to DSM-V (see appendix 1):
A. persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development, as characterized by (1) and/or (2):
1. Attention deficit: Six (or more) of the following symptoms have persisted for at least 6 months to a degree that is inconsistent with developmental level and that negatively impacts directly on social and academic/occupational activities:
* Often fails to give close attention to details or makes careless mistakes in schoolwork, at work, or during other activities (e.g., overlooks or misses details, work is inaccurate).
* Often has difficulty sustaining attention in tasks or play activities (e.g., has difficulty remaining focused during lectures, conversations, or lengthy reading).
* Often does not seem to listen when spoken to directly (e.g., mind seems elsewhere, even in the absence of any obvious distraction).
* Often does not follow through on instructions and fails to finish schoolwork, chores, or duties in the workplace (e.g., starts tasks but quickly loses focus and is easily sidetracked).
* Often has difficulty organizing tasks and activities (e.g., difficulty managing sequential tasks; difficulty keeping materials and belongings in order; messy, disorganized work; has poor time management; fails to meet deadlines).
* Often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort (e.g., schoolwork or homework).
* Often loses things necessary for tasks or activities (e.g., school materials, pencils, books, tools, wallets, keys, eyeglasses).
* Is often easily distracted by extraneous stimuli.
* Is often forgetful in daily activities (e.g., doing chores, running errands).
2. Hyperactivity/impulsivity: Six (or more) of the following symptoms have persisted for at least 6 months to a degree that is inconsistent with developmental level and that negatively impacts directly on social and academic/occupational activities. Note. The symptoms are not solely a manifestation of oppositional behavior, defiance, hostility, or failure to understand tasks or instructions.
* Often fidgets with or taps hands or feet or squirms in seat.
* Often leaves seat in situations when remaining seated is expected (e.g., leaves his or her place in the classroom, in the office or other workplace, or in other situations that require remaining in place).
* Often runs about or climbs in situations where it is inappropriate.
* Often unable to play or take part in leisure activities quietly.
* Is often "on the go" acting as if "driven by a motor" (e.g., is unable to be or uncomfortable being still for extended time).
* Often talks excessively.
* Often blurts out an answer before a question has been completed (e.g., completes people's sentences; cannot wait for turn in conversation).
* Often has trouble waiting his/her turn (e.g., while waiting in line).
* Often interrupts or intrudes on others (e.g., butts into conversations, games, or activities; may start using other people's things without asking or receiving permission).
B. Several inattentive or hyperactive-impulsive symptoms were present before age 12 years.
C. Several inattentive or hyperactive-impulsive symptoms are present in two or more settings, (e.g., at home, school or work; with friends or relatives).
D. There is clear evidence that the symptoms interfere with, or reduce the quality of, social, school, or work functioning.
E. The symptoms do not occur exclusively during the course of schizophrenia or another psychotic disorder and are not better explained by another mental disorder (e.g., mood disorder, anxiety disorder, dissociative disorder, personality disorder, substance intoxication or withdrawal).
4\. ADHD-RS-V ≥ 22. 5. Availability of signed information sheet and informed consent form for the parents/adoptive parents for the subject's participation in the clinical trial.
Exclusion Criteria
1. History of central nervous system (CNS) diseases including:
* Inflammatory diseases of the central nervous system (G00-G09).
* Systemic atrophies primarily affecting the CNS (G10-G13).
* Extrapyramidal and movement disorders (G20-G26).
* Other degenerative diseases of the nervous system (G30-G32).
* Demyelinating diseases of the CNS (G35-G37).
* Epilepsy (G40-41).
* Hydrocephalus (G91).
2. Childhood autism (F84.0), atypical autism • (F84.1).
3. Mental retardation (F70-79).
4. Disorders of psychological development (F80-F89).
5. History of hyperthyroidism (thyrotoxicosis).
6. History/suspicion of oncology of any location (except for benign neoplasms).
7. Any other comorbidity which, in the opinion of the investigator, may affect patient participation in the clinical trial.
8. Patients allergic to/intolerant of any constituent of the medications used in the treatment.
9. Hereditary lactose intolerance, malabsorption due to lactose intolerance including congenital or acquired lactase (or other disaccharide) deficiency, galactosemia.
10. Patients whose parents/adoptive parents will not fulfill the requirements during the study or follow the order of administration of the study drug (SD) products, from the Investigator's point of view.
11. History of treatment noncompliance, mental diseases, alcoholism or drug abuse in parents/adoptive parents which, according to the investigator, will prevent from following the study procedures.
12. Administration of the products outlined in section "Prohibited concomitant therapy" within 1 month prior to enrollment.
13. Patients who have participated in other clinical trials in the past 3 months.
14. The patient's parent/adoptive parent is a study specialist of the center and is directly involved in the study, or is an immediate family member of the Investigator. Spouses, parents, children, or siblings, regardless of whether they are siblings or adopted are considered immediate family members.
15. The patient's parent/adoptive parent works at Materia Medica Holding, i.e. they are employees of the Company, temporary employees on a contract basis or appointed officials responsible for conduction of the study or their immediate family members.
* Inflammatory diseases of the central nervous system (G00-G09).
* Systemic atrophies primarily affecting the CNS (G10-G13).
* Extrapyramidal and movement disorders (G20-G26).
* Other degenerative diseases of the nervous system (G30-G32).
* Demyelinating diseases of the CNS (G35-G37).
* Epilepsy (G40-41).
* Hydrocephalus (G91).
2. Childhood autism (F84.0), atypical autism • (F84.1).
3. Mental retardation (F70-79).
4. Disorders of psychological development (F80-F89).
5. History of hyperthyroidism (thyrotoxicosis).
6. History/suspicion of oncology of any location (except for benign neoplasms).
7. Any other comorbidity which, in the opinion of the investigator, may affect patient participation in the clinical trial.
8. Patients allergic to/intolerant of any constituent of the medications used in the treatment.
9. Hereditary lactose intolerance, malabsorption due to lactose intolerance including congenital or acquired lactase (or other disaccharide) deficiency, galactosemia.
10. Patients whose parents/adoptive parents will not fulfill the requirements during the study or follow the order of administration of the study drug (SD) products, from the Investigator's point of view.
11. History of treatment noncompliance, mental diseases, alcoholism or drug abuse in parents/adoptive parents which, according to the investigator, will prevent from following the study procedures.
12. Administration of the products outlined in section "Prohibited concomitant therapy" within 1 month prior to enrollment.
13. Patients who have participated in other clinical trials in the past 3 months.
14. The patient's parent/adoptive parent is a study specialist of the center and is directly involved in the study, or is an immediate family member of the Investigator. Spouses, parents, children, or siblings, regardless of whether they are siblings or adopted are considered immediate family members.
15. The patient's parent/adoptive parent works at Materia Medica Holding, i.e. they are employees of the Company, temporary employees on a contract basis or appointed officials responsible for conduction of the study or their immediate family members.
Minimum Eligible Age
7 Years
Maximum Eligible Age
12 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Materia Medica Holding
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital "Russian Railways - Medicine" of the city of Bryansk
Bryansk, , Russia
Site Status
Regional Clinical Specialized Psychoneurological Hospital # 1/Children's dispensary department
Chelyabinsk, , Russia
Site Status
Engels Psychiatric Hospital
Engel's, , Russia
Site Status
Kazan State Medical University/Department of Neurology, Neurosurgery and Medical Genetics
Kazan', , Russia
Site Status
Children's Republican Clinical Hospital/Neurological department for the treatment of patients with CNS lesions with mental disorders
Kazan', , Russia
Site Status
Specialized Clinical Psychiatric Hospital # 1/Dispensary department
Krasnodar, , Russia
Site Status
Russian National Research Medical University named after N.I. Pirogov/Department of Neurology, Neurosurgery and Medical Genetics, Faculty of Pediatrics
Moscow, , Russia
Site Status
Research and Practical Center of Pediatric Psychoneurology of Moscow City Health Department/Consultative and polyclinic department
Moscow, , Russia
Site Status
Moscow Regional Research Clinical Institute named after M.F. Vladimirsky/Neurology Department of Therapy Department
Moscow, , Russia
Site Status
Llc "Nizhmedklinika"
Nizhny Novgorod, , Russia
Site Status
Privolzhsky Research Medical University/Department of Neurology, Psychiatry and Narcology FDPO
Nizhny Novgorod, , Russia
Site Status
Orenburg Regional Clinical Psychiatric Hospital # 1/Children's psychiatric department
Orenburg, , Russia
Site Status
Perm State Medical University named after academician E.A. Wagner/Department of Neurology
Perm, , Russia
Site Status
LLC "Treatment and rehabilitation research center "PHOENIX"/Day hospital # 1
Rostov-on-Don, , Russia
Site Status
Ryazan State Medical University named after Acad. I.P. Pavlov/Department of Children's Diseases with a course of hospital pediatrics
Ryazan, , Russia
Site Status
National Medical Research Center for Psychiatry and Neurology named after V.M. Bekhterev
Saint Petersburg, , Russia
Site Status
Llc "Doctrina"
Saint Petersburg, , Russia
Site Status
Institute of the Human Brain named after N.P. Bekhtereva
Saint Petersburg, , Russia
Site Status
LLC "DNA Research Center"
Saratov, , Russia
Site Status
Saratov State Medical University named after V.I. Razumovsky/Department of Neurology. named after K.N. Tretyakov
Saratov, , Russia
Site Status
City Clinical Hospital # 2 named after V.I. Razumovsky
Saratov, , Russia
Site Status
Saratov City Psychoneurological Dispensary
Saratov, , Russia
Site Status
Smolensk Regional Clinical Hospital/Children's neurological department
Smolensk, , Russia
Site Status
Smolensk Regional Clinical Hospital/Pediatric neurological department
Smolensk, , Russia
Site Status
LLC "Sunterra"
Stavropol, , Russia
Site Status
Stavropol Regional Clinical Specialized Psychiatric Hospital # 1/Children's department # 17
Stavropol, , Russia
Site Status
Regional Clinical Psychoneurological Dispensary/Outpatient clinic # 2
Tver', , Russia
Site Status
Children's City Clinical Hospital of Ulyanovsk city
Ulyanovsk, , Russia
Site Status
Yaroslavl State Medical University/Department of Polyclinic Pediatrics
Yaroslavl, , Russia
Site Status
Sverdlovsk Regional Clinical Psychiatric Hospital/Pediatric and adolescent medical and diagnostic department
Yekaterinburg, , Russia
Site Status
LLC "European Medical Center "UMMC-Health"/Children's polyclinic in the main branch
Yekaterinburg, , Russia
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Russia
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MMH-MAP-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder
NCT00467428
COMPLETED
PHASE2
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
NCT03231800
COMPLETED
PHASE3
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
NCT02402166
COMPLETED
PHASE2
An Effectiveness and Safety Study of CONCERTA* vs. Immediate Release Methylphenidate (IR MPH) in Attention Deficit Hyperactivity Disorder Children
NCT00304681
COMPLETED
PHASE3
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT01244490
COMPLETED
PHASE3
A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD)
NCT02699086
COMPLETED
PHASE2
Attention Deficit Disorder Medication Response Study
NCT01727414
COMPLETED
PHASE4
Safety and Efficacy of Methylphenidate in Children With Attention-deficit Hyperactivity Disorder (ADHD)
NCT00428792
COMPLETED
PHASE3
The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
NCT00928148
COMPLETED
PHASE2
NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
NCT01835548
COMPLETED
PHASE3
Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17
NCT00150592
COMPLETED
PHASE2
Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia
NCT00856973
COMPLETED
PHASE3
Dasotraline Pediatric ADHD Study
NCT02428088
COMPLETED
PHASE2/PHASE3
Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17
NCT00152009
COMPLETED
PHASE3
The Effects of a Single Dose of Methylphenidate on Motor Performance
NCT04283604
RECRUITING
PHASE4
A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).
NCT00531752
COMPLETED
PHASE2
Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity
NCT03662763
COMPLETED
PHASE3
Mazindol in Children With ADHD : Open-label, Efficacy, Safety and Pharmacokinetic Pilot Trial
NCT00508677
COMPLETED
Attention-Deficit/Hyperactivity Disorder (ADHD) Brain Activity Changes to Psychostimulants
NCT01310439
COMPLETED
Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder
NCT02951754
RECRUITING
PHASE4
Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)
NCT01243242
COMPLETED
PHASE2
Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT01274221
WITHDRAWN
PHASE3
KP415 Classroom Study in Children (6-12 Years of Age) With ADHD
NCT03292952
COMPLETED
PHASE3
Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects
NCT00995085
COMPLETED
PHASE1
Stimulant Drug Treatment of Attention-Deficit Hyperactivity Disorder (AD/HD), Inattentive Type
NCT00824317
COMPLETED
NA